Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.

@article{Reddy1999ChemopreventiveEO,
  title={Chemopreventive efficacy of sulindac sulfone against colon cancer depends on time of administration during carcinogenic process.},
  author={B. Somasekhara Reddy and Toshihiko Kawamori and Ronald A. Lubet and Vernon E. Steele and Gary j. Kelloff and Chinthalapally V Rao},
  journal={Cancer research},
  year={1999},
  volume={59 14},
  pages={3387-91}
}
Epidemiological and model studies with laboratory animals have provided evidence that nonsteroidal anti-inflammatory drugs reduce the risk of colon cancer. Sulindac, a nonsteroidal anti-inflammatory drug, has been shown to inhibit azoxymethane (AOM)-induced colon carcinogenesis in rats when administered continuously before, during, and after carcinogen treatment (initiation and postinitiation periods) or when given continuously beginning 14 weeks after carcinogen administration (promotion… CONTINUE READING